Bicara Therapeutics Inc [BCAX] stock prices are up 1.22% to $14.91 at the moment. Until recently, the best way to gauge how the stock has performed was to look at its short-term value. The BCAX shares have gain 5.45% over the last week, with a monthly amount drifted -13.86%, and not seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Bicara Therapeutics Inc [NASDAQ: BCAX] stock has seen the most recent analyst activity on August 19, 2025, when Piper Sandler initiated its Overweight rating and assigned the stock a price target of $36. Previously, Wells Fargo upgraded its rating to Equal Weight on May 23, 2025, and kept the price target unchanged to $8. On April 17, 2025, Wells Fargo initiated with a Underweight rating and assigned a price target of $8 on the stock. Wedbush started tracking the stock assigning a Outperform rating and suggested a price target of $31 on February 06, 2025. H.C. Wainwright initiated its recommendation with a Buy and recommended $42 as its price target on December 06, 2024. Rodman & Renshaw started tracking with a Buy rating for this stock on November 05, 2024, and assigned it a price target of $48. In a note dated October 08, 2024, TD Cowen initiated an Buy rating.
The stock price of Bicara Therapeutics Inc [BCAX] has been fluctuating between $7.80 and $24.15 over the past year. Currently, Wall Street analysts expect the stock to reach $24 within the next 12 months. Bicara Therapeutics Inc [NASDAQ: BCAX] shares were valued at $14.91 at the most recent close of the market. An investor can expect a potential return of 60.97% based on the average BCAX price forecast.
Analyzing the BCAX fundamentals
To continue investigating profitability, this company’s Return on Assets is posted at -0.23, Equity is -0.22 and Total Capital is -0.28. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of0.01.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 14.53 points at the first support level, and at 14.16 for the second support level. However, for the 1st resistance point, the stock is sitting at 15.34, and for the 2nd resistance point, it is at 15.78.
Ratios To Look Out For
It’s worth pointing out that Bicara Therapeutics Inc [NASDAQ:BCAX]’s Current Ratio is 14.14. As well, the Quick Ratio is 14.14, while the Cash Ratio is 25.34.
Transactions by insiders
Recent insider trading involved Cohlhepp Ryan, President and COO, that happened on Oct 15 ’25 when 12500.0 shares were sold. Officer, Mazumdar Claire completed a deal on Oct 16 ’25 to buy 24103.0 shares. Meanwhile, Chief Executive Officer Mazumdar Claire sold 13289.0 shares on Oct 15 ’25.
